Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19

被引:0
作者
Siddhi Tandon
Anchal Aggarwal
Shubhra Jain
Sanjay Shukla
Sarika Chaudhary
机构
[1] Bennett University,Department of Biotechnology, School of Engineering and Applied Sciences
来源
The Protein Journal | 2020年 / 39卷
关键词
Antibody; SARS-CoV-2; Convalescent plasma; COVID-19; Cytokine; Therapeutic drug;
D O I
暂无
中图分类号
学科分类号
摘要
The sudden emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease of 2019 (COVID-19) has brought the world to a standstill. Thousands of people across the globe are biting the dust with every passing day and yet more are being tested positive for the SARS-CoV-2 infection. In order to dispense this current crisis, numerous treatment options have been tried and tested and many more are still under scrutiny. The development of vaccines may help in the prevention of the global pandemic, however, there is still a need for the development of alternate approaches to combat the disease. In this review we highlight the new discoveries and furtherance in the antibody based therapeutic options and the potent drugs, with special emphasis on the development of the monoclonal and polyclonal antibodies and the repurposed drugs, which may prove to be of significant importance for the treatment of COVID-19, in the days to come. It is an attempt to evaluate the currently presented challenges so as to provide a scope for the ongoing research and assistance in the development of the effective therapeutic options against SARS-CoV-2.
引用
收藏
页码:631 / 643
页数:12
相关论文
共 525 条
[1]  
Chen Y(2020)Emerging coronaviruses: genome structure, replication, and pathogenesis J Med Virol 92 418-423
[2]  
Liu Q(2005)Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia J Clin Microbiol 43 3054-3058
[3]  
Guo D(2020)The proximal origin of SARS-CoV-2 Nat Med 26 450-452
[4]  
Woo PC(2020)Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Science (New York, N.Y.) 367 1260-1263
[5]  
Lau SK(2020)Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects Expert Opin Biol Ther 130 1545-1548
[6]  
Wong BH(2020)The convalescent sera option for containing COVID-19 J Clin Investig 5 CD013600-18
[7]  
Tsoi HW(2020)Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review Cochrane Database Syst Rev 38 10-385
[8]  
Fung AM(2020)Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) Asian Pac J Allergy Immunol 9 382-280.e8
[9]  
Kao RY(2020)Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Emerg Microbes Infect 181 271-576
[10]  
Chan KH(2020)SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell 12 571-650